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Abstract
Background: In the past decade the Göttingen minipig has gained increasing recognition as animal model in
pharmaceutical and safety research because it recapitulates many aspects of human physiology and metabolism.
Genome-based comparison of drug targets together with quantitative tissue expression analysis allows rational
prediction of pharmacology and cross-reactivity of human drugs in animal models thereby improving drug attrition
which is an important challenge in the process of drug development.
Results: Here we present a new chromosome level based version of the Göttingen minipig genome together with a
comparative transcriptional analysis of tissues with pharmaceutical relevance as basis for translational research. We relied
on mapping and assembly of WGS (whole-genome-shotgun sequencing) derived reads to the reference genome of the
Duroc pig and predict 19,228 human orthologous protein-coding genes. Genome-based prediction of the sequence of
human drug targets enables the prediction of drug cross-reactivity based on conservation of binding sites. We further
support the finding that the genome of Sus scrofa contains about ten-times less pseudogenized genes compared to
other vertebrates. Among the functional human orthologs of these minipig pseudogenes we found HEPN1, a putative
tumor suppressor gene. The genomes of Sus scrofa, the Tibetan boar, the African Bushpig, and the Warthog show
sequence conservation of all inactivating HEPN1 mutations suggesting disruption before the evolutionary split of these
pig species. We identify 133 Sus scrofa specific, conserved long non-coding RNAs (lncRNAs) in the minipig genome and
show that these transcripts are highly conserved in the African pigs and the Tibetan boar suggesting functional
significance. Using a new minipig specific microarray we show high conservation of gene expression signatures in 13
tissues with biomedical relevance between humans and adult minipigs. We underline this relationship for minipig and
human liver where we could demonstrate similar expression levels for most phase I drug-metabolizing enzymes. Higher
expression levels and metabolic activities were found for FMO1, AKR/CRs and for phase II drug metabolizing enzymes in
minipig as compared to human. The variability of gene expression in equivalent human and minipig tissues is
considerably higher in minipig organs, which is important for study design in case a human target belongs to this
variable category in the minipig. The first analysis of gene expression in multiple tissues during development from young
to adult shows that the majority of transcriptional programs are concluded four weeks after birth. This finding is in line
with the advanced state of human postnatal organ development at comparative age categories and further supports the
minipig as model for pediatric drug safety studies.
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Conclusions: Genome based assessment of sequence conservation combined with gene expression data in
several tissues improves the translational value of the minipig for human drug development. The genome
and gene expression data presented here are important resources for researchers using the minipig as model
for biomedical research or commercial breeding. Potential impact of our data for comparative genomics,
translational research, and experimental medicine are discussed.
Keywords: Comparative genomics, Transcriptional profiling, Pseudogene, Long non-coding RNA, Drug
development and safety, Minipig
Background
A critical step in drug development is the transition
from the pre-clinical phase into clinical trials requiring
experimental evidence that the drug candidate is reason-
ably safe in humans. Once a therapeutic indication, a
biological effect, and a drug target or phenotype are
defined, high-throughput screening and information-
driven design techniques are employed to identify new
chemical and biological starting points, which are fur-
ther optimized to leads with the desired activity, e.g. as
agonist or antagonist. Then, in line with regulatory re-
quirements, appropriate animal models play a key role
in pre-clinical development to ensure drug efficacy and
safety. A wide range of animal models is considered for
pharmacological efficacy studies including fish, rats, rab-
bits, and genetically engineered small- and large animal
models such as mice and pigs [1–3]. For toxicological
drug safety studies, however, the range of animal models
is more restricted usually to a rodent and a non-rodent
species since a well-defined battery of tests is required
by guidelines of government agencies [4]. The most
common animal species used to assess pre-clinical drug
safety are rat as rodent species and beagle dogs and the
Cynomolgus monkey (Macaca fascicularis) are accepted
non-rodent models. In the last years the Göttingen mini-
pig has gained growing attention as model for drug
safety testing and translational medical research fueled
by the RETHINK consortium [5]. These animals resem-
ble many features of human anatomy, physiology, and
biochemistry [5,6]. Furthermore, the status of pigs as
livestock animals may relieve some ethical concerns as-
sociated with the use of dogs or primates as subjects for
pre-clinical drug safety [7–9]. Multiple reciprocal crosses
between Minnesota minipigs, Vietnamese potbelly pigs
and German landrace pigs performed at the University
of Göttingen gave rise in the 1990s to the founder mini-
pigs of the Denmark based commercial breeding com-
pany Ellegaard [10]. Since then, minipigs with well
documented breeding history are produced under high-
est hygienic and accredited animal welfare standards,
thus fit for use in safety testing.
Following the advent of high-throughput genetic tools,
genomic characterization of animal models has become
indispensable for breeding purposes and has significantly
improved interpretation of experimental data with re-
spect to the translational value and relevance to human.
In addition, genomic approaches significantly support
rational species selection especially in the area of drug
efficacy and safety. Primary sequence comparison of hu-
man drug target sequences with orthologs of animal
models, for instance, allows prediction of drug cross-
reactivity and responder species selection. Moreover,
comparison of quantitative tissue expression profiles be-
tween humans and animal models allow the prediction
or retrospective interpretation of tissue-specific pharma-
codynamic and pharmacokinetic responses as well as
modeling of drug exposure. In addition, identification
and annotation of human orthologs enables design of
species-specific analytical tools such as DNA microar-
rays or quantitative PCR assays.
Extensive breeding of domestic animals has generated
significant phenotypic and genetic differences [11–14].
The first minipig genome sequence has recently been pub-
lished by Vamathevan et al. [15] after the genomes of the
domestic Duroc pig [11] and the Tibetan wild-boar [12].
According to Vamathevan et al., the Göttingen minipig
genome lacks ~3000 protein coding genes when com-
pared to the domestic pig and the Tibetian boar. A pos-
sible source for this significant discrepancy is the complex
breeding history of the Göttingen minipig resulting in loss
of non-essential genes. However, a more plausible explan-
ation are different settings in algorithms for the prediction
of human orthologous, multi-copy, and species-specific
genes, or gaps and assembly inaccuracies, especially for a
fully de novo assembled genome without chromosomal
anchoring. Correct protein-coding gene predicitions in
model organisms are crucial for translational medicine
and therefore we generated a new chromosome anchored
version of the minipig genome sequence termed Roche
minipig genome. Using this assembly we identified about
2000 additional protein coding genes thereby approaching
the gene count of Sus scorfa and the Tibetian boar. In
addition we have used the Roche-genome combined with
RNA-sequencing to design a minipig-specific microarray
for transcriptional profiling in adult minipig tissues and
during development from young to adult. Moreover, we
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describe minipig-specific lncRNAs and pseudogenes
which are conserved in all available porcine genomes. The
value of the minipig for translational research and as a
model for drug safety assessment is discussed from a gen-
omic perspective.
Results
The Roche minipig genome and comparative genomics
Recently, full-genome sequences of the Duroc farming
pig [11], the Tibetan wild-boar [12], and the Göttingen
minipig [15] were published. Using different methods,
these genomes are predicted to harbor 21,640, 21,806,
or 18,150 protein-coding genes for the Duroc pig, the
Tibetan pig, and the Göttingen minipig, respectively.
To explore this discrepancy we have generated a new
minipig genome sequence using liver DNA isolated
from a female minipig with documented breeding his-
tory from the commercial supplier Ellegaard. We used
a combined Roche-454 and SOLiD sequencing ap-
proach and mapped all sequence reads on the latest
version of the Duroc pig genome (Sus scrofa 10.2)
which is the only available porcine genome assembly at
the chromosome level. The mapping rate is ~93 % for
Roche-454 reads and ~63 % for SOLiD reads resulting
in total in ~20-fold genome coverage (Additional file 1:
Tables S1 and Additional file 2: Table S2). For compara-
tive genomics and gene identification we scanned our
minipig genome together with the three other porcine
genomes using a BLAST procedure [16]. 20,786 pig
gene sequences from ENSEMBL were mapped to the
Duroc pig genome with extremely high significance.
From these 20,786 gene sequences 589 (2.8 %) could
not be mapped on the Roche minipig genome draft
(Additional file 3: Table S3); 441 of these 589 gene
sequences are uncharacterized or not annotated
genes. Therefore our Roche minipig genome scores a
bit lower than the assemblies of the Tibetan pig (454
unmapped genes) and the de novo assembled minipig
(449 unmapped genes), but on the other hand ex-
hibits a slightly higher level of sequence identity of
the mapped sequences (Additional file 4: Figure S1).
To explore the overall sequence conservation of minipig
protein-coding genes compared to other major pre-clinical
animal models and humans, sequence identity of minipig,
dog, macaque and rodent transcriptomes with respect to
human has been calculated for ~ 35,700 orthologous
mRNAs (including splice variants) and ~ 28,400 proteins.
As expected, the 5’- and 3’- untranslated RNA (5’ UTR, 3’
UTR) sequences (UTRs) exhibit lower identities than the
coding sequences (CDS) and also lower identities for ro-
dents with modes at ~74 %, than for macaques, with modes
at ~94 %. For minipigs and dogs, UTR sequence identities
were quite similar with modes at ~78 % (Fig. 1a). The CDS
showed sequence identities of 88 % for rodents, 91 % for
minipigs, 92 % for dogs and 98 % for macaques. At the pro-
tein level higher sequence identities with modes >97 % are
calculated for all animal models.
For more reliable selection of an appropriate animal
model for preclinical research primary sequence align-
ments should be complemented by the analysis of func-
tional domains, small molecule binding pockets or
epitopes targeted by therapeutic antibodies. For ex-
ample, the X-ray co-crystal structure of the peroxisome
proliferator-activated receptor alpha (PPARα) with the
dual PPARα/γ agonist aleglitazar revealed its binding
mode and 25 amino acids in contact with the ligand
(distance ≤ 4.5 Å). These amino acids are fully con-
served in human, macaques, dog, and minipig while in
rodents three residues (I272F, T279M, V332I) are differ-
ent (Fig. 1b). This difference likely explains the 45-fold
lower receptor affinity of the agonist in mouse and rat
compared to human [17] (Fig. 1b). Similarly, interspe-
cies sequence conservation analysis of the residues
forming the epitopes of therapeutic antibodies targeting
soluble vascular endothelial growth factor (VEGF) pro-
vides possible explanation for experimentally measured
differential affinity (Fig. 1c). Avastin (mAB 4.6.1) is used
for cancer therapies, and Lucentis (Y0317) is the gold
standard drug for treatment of age-related macular de-
generation. L3H6 is an affinity-improved single-chain
variable antibody fragment and G6 is a Fab fragment,
both isolated from recombinant phage display libraries
[18, 19]. Based on the 3D-models shown in Fig. 1c and
affinity data, VEGF residue G88 is critical for high-
affinity binding of Avastin and Lucentis. In rodents, the
conserved glycine residue is changed to serine explain-
ing the poor cross-reactivity of both therapeutic anti-
bodies [18, 20]. The picture for L3H6 is more complex
because high-affinity binding involves seven contact
sites. Three out of these seven contact sites are changed
in rodents (E72S, N100S, K101R) in agreement with the
low cross-reactivity found experimentally. In G6, the
contact sites on the VEGF dimer are conserved across
all species included in the alignment, and sequence-
based drug target assessment would predict cross-
reactivity for all species as shown in Fig. 1c. As shown
in the examples highlighted above, inter-species se-
quence conservation analysis can provide predictions of
cross-reactivity of small molecule drugs or therapeutic
antibodies given that the binding site residues are
known.
Disrupted genes/pseudogenes
Species differences in genes encoding human drug-
targets are a critical parameter for species selection for
translational research and preclinical drug development,
especially when genes have become non-functional
Heckel et al. BMC Genomics  (2015) 16:932 Page 3 of 19
Fig. 1 Multi-species sequence comparisons and assessment on drug binding. a Sequence identities between 1:1 orthologous transcripts and
proteins of human, Rhesus macaque, Cynomolgus macaque, minipig, rat, and mouse. The 5’ UTR, CDS, and 3’ UTR of ~35,700 orthologous mRNAs
(including splice variants) and of ~28,400 orthologous proteins were considered separately for the calculation of pairwise sequence identities in
comparison to human. The relative number of 1:1 orthologous sequences was plotted against the sequence identities. Note that the peak
sequence identities for the UTRs are significantly lower between humans and non-primates than for the coding regions. b Peroxisome
proliferator-activated receptor alpha (PPARα) small molecule binding pocket analysis across multiple species. X-ray crystal structure of the ligand
binding domain of human PPARα (magenta) with the dual PPARα/γ agonist aleglitazar (cyan) and with a 13-residue fragment of the SRC1 receptor co-
activator motif 3 (green). Sequence alignments of PPARα orthologs from multiple species indicate that the contact residues (*) are fully conserved
between human, macaques, and pigs while mouse and rat have sequence differences at three positions (P272, M279, I332) in comparison to the other
species (I272, T279, V332). The inset shows the binding cavity in more detail and the non-conserved amino acids highlighted in a stick representation.
PDB code: 3G8I. c Vascular endothelial growth factor (VEGF) epitope analysis for four different antibodies across multiple species. Depicted is the
surface of human VEGF homodimer (light grey/dark grey) with residues relevant for antibody binding colored in red. Sequence alignments
of VEGF orthologs from multiple species indicate for each antibody good conservation of contact residues (*) in human, macaques, and
pigs, but not in rodents. Therefore cross-species reactivity is poor for mAb 4.6.1, the parent antibody of Avastin, and Y0317 (Lucentis) which
are a product of immune response against hVEGF in mouse, and for the single-chain variable fragment (scFv) L3H6, targeting a different
less conserved epitope. G6-Fab, derived from a synthetic antibody phage library, however shows good cross-reactivity due to full conservation of the
functional epitope. PDB code: 1FLT
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during evolution or breeding. Therefore the Roche mini-
pig genome was scanned for non-functional, gene-like
sequences. This analysis revealed 441 annotated pseudo-
genes in minipig consistent with published data for por-
cine genomes [11, 12, 15] (Additional file 3: Table S3).
We further expanded our investigation for pseudo-
genes with protein-coding human orthologs that con-
tain frame shift mutations or premature stop codons
affecting protein translation and integrity in both the
Duroc pig and our minipig genome, which are not
represented in the pig protein NCBI-RefSeq database
to reduce false positive discovery. This screen yielded
12 genes that are not functional in pigs as opposed
to human (Additional file 5: Table S4). Among them,
we found HEPN1, a tumor suppressor in hepatocellu-
lar carcinoma and pituitary somatotroph adenomas
based on genetic evidence [21, 22]. In the minipig
and Duroc farming pig the sequence of the HEPN1
gene shows a start codon mutation, two stop codons
generating G/A mutations, and three frame-shifting
insertions/deletions (Additional file 6: Figure S2).
Since tumors in general and liver tumors in particular
are of a comparatively low incidence in pigs [23–25],
it is conceivable that HEPN1 function became
dispensable early in porcine evolution. It is also pos-
sible that the inactive HEPN1 allele was introduced
recently in commercial pig breeds as a result of ex-
tensive breeding over the last ~10,000 years [11].
Therefore we assembled the coding region of the
HEPN1 gene from whole-genome-shotgun (WGS-) se-
quencing libraries from the African Warthog (Phaco-
choerus africanus) and two Bushpigs (Potamochoerus
larvatus), because African and Eurasian pigs have
evolved independently for at least ten million years
without any reported contact or crosses [26, 27]. The
DNA sequence and the position of all six HEPN1
mutations are identical in both African pig species
and the Eurasian breeds (Additional file 6: Figure S2)
indicating that HEPN1 was inactivated before the split
into Eurasian and African pig species.
Porcine specific transcripts
In primates, a global search in tissue expression databases
yielded 131 primate-specific, polyadenylated, non-coding
RNAs preferentially expressed in reproductive tissues [28].
Whilst microRNAs and small nucleolar RNAs are generally
well-conserved in higher vertebrates long non-coding
RNAs show high conservation within a genus [29]. To
identify porcine specific transcripts in domestic pigs we
followed the experimental strategy by Tay et al. [28] and se-
quenced minipig testis RNA on three different sequencing
platforms (Additional file 7: Figure S3). Minipig sequences
were assembled and mapped on several vertebrate genomes
to end up with 133 non-coding porcine-specific transcript
candidates. Because primate specific transcripts are highly
conserved across many primate species, we mapped our
133 lncRNA sequences to all the available porcine genome
sequences. In the Roche minipig genome 130 out of 133
loci are detected in the genome with 100 % sequence iden-
tity followed by the Duroc pig (127 out of 133) and the
Tibetan boar (124 out of 133; Additional file 8: Figure S4).
In the Göttingen minipig genome, 126 lncRNAs are
detected matching 100 % and about 15RNAs are detected
with partial homology. For example, the lncRNA
G8MPFOXO1AQL9 appears to be absent in the genome of
Duroc, the Tibetan boar and our minipig whilst present in
the Göttingen minipig genome from Vamathevan et al., and
yet it is present in three independent testis RNA sequen-
cing libraries. For the African Warthog and the Bushpig,
we compared all available reads coming from our WGS ex-
periment to the sequences of all 133 minipig lncRNAs to
cope with lack of an assembled genome. One hundred
twenty one lncRNAs had perfect matches with reads from
these random libraries above an arbitrary detection thresh-
old (Additional file 9: Table S5). This reversed mapping ap-
proach does not allow a conclusive statement about
sequence conservation except that all mapping reads had at
least 95 % identity (data not shown). We conclude that the
pig family possesses like primates specific transcripts with
comparable abundance and considerable sequence conser-
vation in Eurasian and African species.
Comparative analysis of gene expression in human and
minipig tissues
Gene expression profiles across multiple tissues allow
the prediction of shared functional properties of ani-
mal and human tissues including prediction of tissue-
specific drug responses. For a comprehensive analysis
of the minipig transcriptome in one year-adults, we
constructed minipig specific gene expression microar-
rays to build a minipig gene expression database with
a set of 18 tissues with high relevance for biomedical
research (aorta, cerebrum, cerebellum, colon, duode-
num, gall bladder, heart, jejunum, kidney, liver, lung,
ovary, skeletal muscle, spleen, stomach, testis, thyroid
glands, and urinary bladder). We used 12 biological
replicates per tissue (six male and six female) to sup-
port statistical data analysis with concomitant detec-
tion of inter-individual variability. Inspection of the
first three principal components, accounting for 29 %
of the observed variability in the expression profiles
of 18 tissues, revealed that biological replicates and
biologically related tissues from the same organ sys-
tem cluster together (data not shown). Interestingly,
brain and testis tissue transcriptomes were most dif-
ferent to the other minipig tissues in the principal
component analysis (PCA). To compare minipig tis-
sue expression profiles to their human counterparts,
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we used a high quality human microarray dataset
with 13 overlapping tissues and 16,032 shared genes
[30]. Both datasets were normalized first within and
second across both species with the global rank in-
variant set normalization (GRSN) method to reduce
systematic distortions in microarray data [31]. The
PCA of the GRSN normalized expression data showed
that principal component 1 separates the two species
whilst principal component 2 and principal component 3
show very similar clustering of human and minipig tissue
transcriptomes reflecting also the special complexity of
brain and testis in both species (Fig. 2a). We extracted sig-
nature genes with significant enrichment in specific tissues
from several human tissue expression data sets available
in public databases. These signatures allowed the deter-
mination of minipig tissue transcriptomes with gene
Fig. 2 Global Comparison of human and minipig tissue expression profiles. a Principal component analysis of whole transcriptome expression
profiles of human (n = 3 - 9) and minipig tissues (n = 9 - 12) based on 16’032 orthologous genes. A common set of 13 tissue types is represented
for each species. Tissues types were colored according to organ systems. Principal component 1 accounts for 29 %, principal component 2 for 11 %,
and principal component 3 for 6 % of the variation of the data set. Related tissues cluster together between species. b Comparison of minipig whole
transcriptome expression profiles to human tissue signatures. Enrichment scores are indicated by a relative color scale (by row); with red representing
high similarity and white no similarity of minipig gene expression profiles to human tissue specific gene expression signatures
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expression profiles similar to human. Using this approach
combined with unsupervised clustering demonstrates high
similarity of human and minipig tissues at the transcrip-
tional level (Fig. 2b). Moreover, the conserved tissue spe-
cific gene signatures in minipig support similarity of core
organ functions to human together with similarities in
metabolism and physiology.
Hepatic drug metabolism in minipig and human
Several studies indicate that the activity of drug me-
tabolizing enzymes and liver physiology is similar
between pigs and humans [32–34]. In general, the
mRNA expression levels of major cytochrome p450
enzymes (CYPs), 12 aldoketo-/carbonyl-reductases, flavin-
containing monooxygenases (FMOs), aldehyde oxidase 1
(AOX1), seven major UDP-glucuronosyltransferases
(UGTs), two N-acetyltransferases (NAT1, NAT2), and five
sulfotransferase 1 family members (SULTs) are similar in
humans and minipigs with the exception of the inducible
CYP2B6 isoform (Fig. 3, left panel). In contrast, mRNA
expression levels of the UGT-isozymes UGT1A6,
UGT2A1, UGT2A3, and UGT2B17 and the rest of the se-
lected drug metabolizing enzymes (FMO1, aldoketoreduc-
tase AKR1C1, carbonylreductase CBR3, sulfotransferases
SULT1C4 and SULT1E1) are significantly higher in mini-
pig liver compared to human. In order to correlate mRNA
abundance with enzymatic activity, we measure the
metabolic activity of a subset of enzymes for which
specific reporter substrates are available (midazolam
[CYP3A4], dextromethorphan [CYP2D6, UGT], diclo-
fenac [CYP2C9], tolbutamide [CYP2C9], buproprion
[CYP2B6], tacrine [CYP1A2], benzydamine [FMO1/3],
daunorubicin [AKR/CR], O6-benzlyguanine [AO],
sulfamethazine [NAT2 ], SN-38 [UGT1A1] and 7-
hydroxycoumarin [UGT,SULT]). For the selected set
of enzymes, the mRNA expression levels and the
metabolic activity correlated well between human and
minipig liver with some exceptions (Fig. 3). The activ-
ities of CYP3A4 and CYP2C9 for instance are lower
in minipig liver whilst the activities of CYP2B6 and
CYP1A2 are elevated. Proportional to differential
mRNA expression, the metabolic formation rate of
benzydamine N-oxide catalyzed by FMO1 and FMO3
[35] is 153-fold higher in minipig liver. Based on the
examples above, mRNA expression levels might serve
as surrogate to predict the metabolism of human
drugs in minipig liver provided that the catalyzing en-
zyme is known.
Tissue specific changes in gene expression from young to
adult
Studies in juvenile animals are needed when existing
data from animals and humans are insufficient to pre-
dict efficacy and safety of drugs in children. Minipigs
have favorable biological characteristics for juvenile
toxicity studies such as a relatively large litter size of
4-6 piglets/sow, cross-fostering of randomly allocated
piglets for genetically heterogeneous group composi-
tions, a “brain growth spurt” similar to neonatal
humans, rapid growth and development, sexual ma-
turity at an early age, and easy handling of piglets.
The developmental stage of a 6 year old human child,
for example, corresponds to a minipig at the age of
about 2 months [36]. Since many organ systems such
Fig. 3 Correlation of transcript abundance and metabolic activity for major drug metabolizing enzymes in human and minipig liver. Liver mRNA
abundance of all major phase I and II drug metabolizing enzymes was determined with minipig and human microarray data (left panel).
Metabolite formation rates (pmol/min/mg protein) were determined for phase I and II enzyme substrates for human and minipig primary
hepatocyte suspension cultures (right panel). Transcript abundance and metabolic activities of human and minipig major cytochrome p450
enzymes (CYPs), aldoketoreductases (AKR/CR), aldehyde oxidase (AOX), N-acetyltransferases (NATs), and sulfotransferases (SULT) are shown as black
dots. UDP-glucuronosyltransferase (UGT) family members are shown as red dots, UGT1A1 as separate blue dots, and flavin-monooxygenase 1
(FMO1) as green dots. Liver mRNA expression levels show higher expression for FMO1, UGTs, SULT1C4, and SULT1E1 in minipig as compared to
human. The UGT family expression data is represented by four subtypes detected by isoform specific probes. All major phase I CYPs show very
similar expression levels in both species. Higher UGT, AKR, and FMO1 enzyme activities compare well with higher liver gene expression levels in
minipig. Bars present average transcript abundance and metabolic activity
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as brain or the reproductive system are still develop-
ing in pediatric populations, they may be prone to
pharmacodynamic effects or toxicities not evident in
studies in adults [37]. Apart from the features above
that are in favor of the minipig as model for juvenile
studies, nothing is known at the molecular level at
which stage after birth organ development is
complete. Especially data regarding the expression of
drug targets, drug metabolism pathways or maturation
of the immune system during development are critical
for rational study design. Therefore, we performed
microarray based tissue expression profiling in 9 tis-
sues relevant for juvenile toxicity assessment (cerebel-
lum, hypothalamus, cerebral cortex, liver, kidney,
spleen, bone marrow, testis, and ovary) from shortly
after birth to adulthood (1 week, 4 weeks, 2 months,
4 months and 2 years). Based on literature, these de-
velopmental stages generally correspond in humans to
a newborn, a 2 year old toddler, a child at the age of
6 years, an adolescent at the age of 14 years/around
puberty and a sexually mature adult [38]. To compare
tissue expression profiles to each other during postna-
tal development, we used PCA. The entire dataset
shows clustering of tissue samples regardless of the
developmental stage suggesting early completion of
the transcriptional programs in the minipig (Fig. 4a).
According to this analysis only testis shows significant
maturation during development which coincides with
the onset of male fertility two months after birth
(pers. communication with Ellegaard and Ellegaard
newsletter 43, spring 2015). This analysis further con-
firms that the specialization of the testis transcrip-
tome in adults as indicated in our PCA analysis
(Additional file 6: Figure S2A and Additional file 8:
Figure S4A) is indeed related to development. Analo-
gous to the multi-tissue analysis in adults (Fig. 2b) we
have used human tissue specific signatures for further
examination of minipig tissue transcriptome matur-
ation (Fig. 4b). This high-level analysis shows first of
all no gender segregation with exception of reproduct-
ive tissues, and secondly and perhaps more important,
that the majority of gene expression programs in the
tissues analyzed are completed shortly after birth ex-
cept for testis, bone-marrow, and spleen. For example
liver transcriptomes share during all time points ana-
lyzed tissue specific expression features with minipig
and human adults. Moreover, the expression of hepatic
genes for drug metabolism and excretion - phase I and
phase II enzymes and drug transporters - reaches adult
levels one week after birth (data not shown). This find-
ing is consistent with limited public data on the devel-
opmental expression of some minipig and human
CYP450 enzymes and drug transporters suggesting that
the major switch-on appears to occur in minipig like in
humans shortly after birth [39, 40]. Compared to most
pathways, maturation of the immune system is delayed
and occurs between four and eight weeks in spleen and
bone-marrow based on human B- and T-cell signatures
(Fig. 3b). In addition, this analysis confirms that testis
specific genes are expressed two months after birth. In
summary, this analysis of gene expression profiles pro-
vides the result that the transcriptional program in
minipigs is basically completed at the age of four weeks
and underlines the advanced state of development in
many organ systems at birth. Based on this outcome,
we conclude that molecular information from develop-
ing piglets further strengthens the interpretation and
translatability of juvenile toxicity studies in minipigs.
Identification of genes with variable expression in
minipig and human tissues
We have previously shown in Macaca fascicularis liver
tissue that about 4 % of the genes show highly variable
expression independent of transcript abundance [41]. To
guide translational research we compared the number of
genes with variable expression in 13 minipig tissues from
9 to 12 animals with matching human microarray data
across 16,032 shared genes (Fig. 4) [30]. Both datasets
were GRSN normalized resulting in a consistent distri-
bution of the mean expression values ensuring compar-
ability within and across species for each tissue. To
identify expression variability the coefficient of variation
(CV) was computed for each gene per tissue and species.
Genes were considered as being highly variable with a
CV > 10 % (Fig. 5). Using this measure of variance, we
find that the number of highly variable genes across 13
tissues is low in both species in cerebellum with about
2–3 % of all genes and high in stomach with up to 30 %
of all genes in minipig. Moreover, ten out of 13 tissues
harbor at least 3-fold more highly variable genes in
minipigs than in humans, which is surprising in light of
low genetic exchange, health monitoring and contolled
environment at the vendor’s breeding center. This differ-
ence is statistically highly significant (p < 0.001) as deter-
mined by a proportionality test and independent of
gender except for reproductive organs. An enrichment
analysis of these lowly-constrained genes for Gene
Ontology (GO) terms reveals certain functional roles for
kidney, ovary, and stomach. For kidney, the sodium/glu-
cose transporter of the transmembrane transport process
(GO:0055085, p < 10−8), the secreted kidney protease
renin, and the peptide hormone angiotensin are highly
variable in both species. This finding points towards a
link between inter-individual differences in diet and the
Renin-Angiotensin-Aldosterone-system controlling the
expression of sodium channels [42]. For ovary, we found
that the annotations for the regulation of growth
(GO:0040008, p < 10−6 ) and for the steroid biosynthetic
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Fig. 4 Gene expression developmentsin minipig organs relevant for juvenile toxicity from young to adult. a Principal component analysis of
whole transcriptome expression profiles of minipig tissues based on 17,254 genes. Principal component 1 accounts for 21.8 %, principal
component 2 for 12.4 %, and principal component 3 for 11.3 % of total variation of the data set. b The heat map shows enrichment scores for
human tissue expression signatures (red = high; white = low) in minipig tissues from young to adult. With exception of reproductive organs
pairwise male and female data points for 1 week, 4 weeks, 2 months, 4 months and adult are shown
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process (GO:0006694, p < 10−5) are most prominently
enriched, indicating inter-individual differences along the
growth hormone axis and the menstrual cycle [43, 44]. Fi-
nally for stomach, the cell adhesion process (GO:0007155,
p < 10−7) seems to be most variable between individuals.
In summary, gene expression variability is considerably
different between organs and should be taken into ac-
count for study design. For example, if a new drug target
belongs to the category of highly variable genes, larger
animal groups are granted to discriminate drug related
findings from inter-individual variability. Genes with
stable expression on the other hand may allow for smaller
experimental groups compliant with the 3R principles of
animal welfare [45].
Discussion and conclusions
In this work we present a comprehensive analysis of the
transcriptional output of the minipig genome covering de-
velopmental and tissue specific gene expression combined
with genome based detection of private pseudogenes and
non-coding transcripts absent in the currently available
genomes of eukaryotic organisms.
As a basis for this study, we have re-sequenced the
minipig genome because any type of gene expression data
rely on correct annotation and specificity of tools and as-
says. Apart from phenotype, most characteristics such as
metabolism or physiology are shared between minipig and
the Duroc pig and therefore we expect no major genomic
differences caused by breeding or environmental adapta-
tion as seen for the olfactory or hypoxia genes in the
Tibetan wild boar [12]. For the Duroc and Tibetan pigs,
21,640 or 21,806 protein-coding genes are predicted,
respectively, which is in good agreement [11, 12]. In con-
trast, Vamathevan et al. predict for their de novo assem-
bled minipig genome 18’150 protein-coding genes [15].
To shed light on this discrepancy with potential im-
pact for research we sequenced the genome of a fe-
male Göttingen minipig by combining Roche-454 long
read pyrosequencing technology for contig and scaf-
fold assembly to the Duroc reference genome and
Fig. 5 Global variability of tissue gene expression profiles in human and minipig. The left bar chart displays the average log2 expression levels,
the middle bar chart the corresponding coefficient of variation (CV) profiles, and the right bar chart high variance genes per tissue and species.
High variance genes were identified from transcriptome-wide expression signals using a 10 % CV cutoff. The number of high variance genes per
tissue and species indicates that cerebellum is the least variable tissue in expression in both species and stomach is the most variable. Notably,
gene expression in minipigs appears in general more variable per tissue than in humans
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SOLiD short read technology to increase sequence
coverage. In the final Roche minipig genome we iden-
tified ~2000 additional protein coding genes resulting
in a final gene count of 20,197 thereby approaching
the gene count in Duroc and Tibetan pigs (Additional
file 3: Table S3). Furthermore, our analysis revealed
441 minipig pseudogenes which is a low number but
consistent across different pig species [11,12,15]. In
contrast, the genomes of Mus musculus and Homo
sapiens contain between 5000 and 11,000 pseudo-
genes, which is at least ten times more than in pigs
[46]. Vamathevan et al. described 340 pseudogenes
encoded in the de novo assembled minipig genome
[15] which is in line with the findings summarized
above. Among this set of pseudogenes only 15 were
described as pseudogenized drug targets including the
genes for dihydrofolate reductase (DHFR), thymidylate
synthetase (TYMS) and prostaglandin synthase 1
(PTGS1) also known as cyclooxygenase 1 (COX1)
[15]. The products of these genes are validated targets
for chemotherapy or the treatment of skin disorders.
Since DHFR and TYMS are essential for de novo thy-
mine nucleotide synthesis, we wished to confirm dis-
ruption of these genes together with PTGS1 in our
assembly of the minipig genome. Indeed, we detected
one DHFR and two TYMS pseudogenes on chromo-
some 1 and on chromosomes 5 and 6, respectively. In
addition, we have identified functional copies encod-
ing DHFR and PTGS1 on chromosomes 2 and 1, re-
spectively. The predicted mRNAs encode open
reading frames of the expected length and sequence
identities of 99.5 % (DHFR) and 100 % (PTGS1) to
the Duroc alleles (data not shown). Furthermore, we
detected DHFR mRNA expression mainly in the cere-
bellum and PTGS1 in minipig gall bladder and lung
corresponding to the pattern in human tissues (data
not shown). In the Duroc pig genome, the TYMS
gene could not be assigned to chromosomes but a
functional allele is instead present within an unplaced
scaffold assembly (NW_003539919.1). Mapping of
minipig RNA sequencing reads to the Duroc TYMS
template enabled reconstruction of the entire coding
sequence. Furthermore, we detected transcripts in
minipig intestine, spleen, liver, lung, ovary, and testis
providing final proof of gene integrity (data not
shown).
Using an unbiased screen across the minipig gen-
ome for pseudogenes with functional human ortho-
logs, we have identified 12 out of 441 minipig
pseudogenes with mutations affecting protein transla-
tion and integrity in both the Duroc and our minipig
genome. These pseudogenes exhibit poor functional
annotation with the exception of the human tumor
suppressor gene HEPN1 [21, 22]. The low incidence
of tumors in pigs [23–25] is consistent with a dis-
pensable function of HEPN1 but maintenance of
identical copies of this disrupted gene in African and
Eurasian pig genomes is puzzling. One plausible
explanation for this result would be the location of
an essential gene on the opposite strand. Indeed, the
last non-coding exon of the minipig ortholog of
HEPACAM (also known as GlialCAM) encoding an
essential human cell adhesion molecule partially over-
laps the coding sequence and 3’-untranslated region
of HEPN1. HEPACAM mRNA is expressed in all tis-
sues included in this study with highest levels in
brain (data not shown). In humans, the HEPACAM
gene product is involved in multiple processes such
as leukoencephalopathy, mental retardation, tumor
suppression and leukodystrophy based on mutations
associated with these disorders [47, 48].
Alternatively, HEPN1 has features of a processed
pseudogene [29]. It has a single exon and we have de-
tected significant levels of HEPN1 non-sense transcripts
in all minipig tissues of this study, especially in the brain
(data not shown). Lethe is an example of a human
pseudogene that produces lncRNAs which bind the tran-
scription factor RelA, inhibiting RelA’s ability to bind
NF-kB gene promoters [49]. Transcription of both
strands at the HEPN1/ HEPACAM locus combined with
possible regulatory functions provides a plausible ex-
planation for the evolutionary stability.
The availability of eukaryotic reference genomes and
of four complete Eurasian pig genome sequences, plus a
collection of WGS reads from the Warthog and the
Bushpig combined with deep RNA sequencing libraries
from liver and testis opened the possibility of identify
transcripts unique to the pig family (Suidae). Since
protein-coding gene sequence divergence between spe-
cies is considered as insufficient to account for substan-
tial lineage- and species-specific phenotypes, much more
attention has been paid to regulatory sequence diver-
gence, gene amplifications, gene loss, and lineage-
specific protein-coding genes [28, 50, 51]. However all
these approaches neglected the potential role of lncRNA
in speciation, which are not well conserved across spe-
cies and which are important regulators of gene expres-
sion [29]. In primates, for example, 131 specific
lncRNAs have been identified that are absent in any
known non-primate genome [28]. Using lncRNA focused
filter criteria we identified 133 lncRNAs in testis tissue
which were present in three independent RNA sequen-
cing libraries and encoded in all available pig genomes
with high sequence conservation in Suidae. The fact that
this number is amazingly close to the yield in primates
and that these lncRNAs are expressed in reproductive
organs implicates a potential function related to
reproduction. Once pluripotent pig stem cells become
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available, genome edited lines can be used for functional
studies of these lncRNAs in cell differentiation and tis-
sue development.
The minipig as model for preclinical safety
The first sequence and annotation of the minipig gen-
ome combined with the Duroc farming pig genome
allow protein sequence alignment with human drug tar-
gets and thereby an assessment of drug cross-reactivity.
The minipig genome sequence presented in this paper
further augments the reliability of genome based predic-
tions regarding translational research. By mapping se-
quence alignments onto X-ray crystal structures we have
shown that the PPARα contact residues for the PPARα/γ
co-agonist aleglitazar are fully conserved between hu-
man and minipig, but different to rodents for three
amino acids. This suggests that the receptor affinity for
minipig might be close to the human value while in
mouse and rat a significant loss of binding was observed.
Along the same line, cross-reactivity of Avastin, a thera-
peutic VEGF-capturing antibody, depends on a single
glycine residue that has been mutated to serine in ro-
dents resulting in abolishment of cross-reactivity.
Whether this human immune reagent shows the pre-
dicted cross-reactivity with the minipig ortholog awaits
experimental verification. Quantitative tissue gene ex-
pression databases are equally important for genome
based selection of a responder species. This paper closes
this gap for the minipig together with the release of
comprehensive tissue gene expression databases as valu-
able resources for the entire biomedical research com-
munity. The possibility of running an in silico expression
analysis across 18 minipig tissues, for instance, allows
the prediction of tissues where exaggerated and adverse
pharmacologic effects of new drugs at their target so
called on-target toxicities are possible. Furthermore
knowledge about the tissue specific expression of drug
metabolizing enzymes such as CYP450 isoforms or anti-
body activating proteases, such as MMP1, can predict
the tissue specific formation of metabolites or activation
of pro-drugs or pro-antibodies once the principal mech-
anisms of drug metabolism and elimination have been
elucidated [52, 53].
Apart from applied science, we have used these data-
bases for comparative medicine. By using a pathway cen-
tered approach and tissue-specific gene expression
signatures, we have shown highly similar gene expression
programs in corresponding human and minipig tissues.
Especially signature genes in colon, heart, liver, and spleen
have particularly high enrichment scores, suggesting simi-
lar biotransformation properties. Our minipig specific mi-
croarrays open for the first time global transcriptional
profiling of drug responses or adverse effects, also referred
to as toxicogenomics. Although quantitative RNA
sequencing is becoming more affordable and user friendly,
this technology exceeds in many cases the needs because
preclinical research is commonly focused on protein tar-
gets. RNA targets, such as the lncRNAs reported here, are
just emerging as therapeutic targets due to the limited un-
derstanding of their biological function [54]. In addition,
data processing and analysis is straightforward and does
not require complex data analysis programs or computing
capacity like current sequencing technologies. An ex-
pected drawback is the low interest in minipig microarray
production by commercial vendors due to the small mar-
ket size as compared to human or rodent platforms. As an
alternative, custom orders are affordable and efficient once
the design is completed and the oligonucleotide pools are
synthesized and available to the scientific community.
Preclinical drug safety assessment in minipigs
For selection of a proper non-rodent model for drug
metabolism and pharmacokinetics, the activity of the
metabolizing enzymes for a given drug is a critical par-
ameter. The elevated activity and mRNA abundance of
FMO, AKR/CR and UGT in minipigs for example, are
expected to affect pharmacokinetics in case one of these
enzymes catalyzes conversion of a drug candidate in hu-
man liver. Thus the gene expression data that cover the
entire set of drug metabolizing enzymes in minipigs and
other non-rodent models are useful to guide selection of
an appropriate species for pharmacodynamic and phar-
macokinetic assessment of new drugs.
Following preclinical drug development, phase I clin-
ical trials show drug safety and toxicity in human volun-
teers. Although data a limited, we have compared the
preclinical systemic and dermal responses of seven mar-
keted drugs targeting different disorders in minipigs and
humans (Table 1). In general, the physiological responses
are comparable and in case of the mTOR inhibitor
Everolimus virtually identical. The availability of the
minipig transcriptome allowed sequence alignment of
the human and the minipig targets showing at least 89 %
similarity. As a consequence, the observed similarity be-
tween the dermal and systemic responses in humans and
minipigs might be related to target pharmacology.
As an additional example related to the minipig as
model for translational research, we compare the expres-
sion levels of genes encoding targets of marketed thera-
peutic antibodies covering a variety of indications
including cancer or cardiovascular disorders (adapted
from Waldmann et al. [55]; for details see legend to
Additional file 10: Figure S5). Overall, the gene expres-
sion levels in colon, kidney, lung, heart, liver and spleen
tissues are highly concordant between human and the
minipig (Additional file 10: Figure S5). Since xenograft
tumor models have not been established in minipigs and
Cynomolgus monkeys, safety testing of tumor targeting
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drug candidates can only address tissue-cross-reactivity
(TCR) and adverse on-target effects but not efficacy.
Since 2006, the regulatory authorities have started
to request preclinical toxicology studies in juvenile
animals because little is known about drug absorp-
tion, distribution, excretion or metabolism in children
showing the need for translational models. The litter
size and early sexual maturity are factors favoring the
minipig as model for pediatric drug safety studies. In
most tissues the gene expression programs are com-
pleted between two and four weeks after birth with
the exception of the immune system. In contrast to
humans, pigs possess an epitheliochorial placenta that
is impermeable for maternal immunoglobulins. As a
result, piglets are born without innate immunity and
protection is achieved by delivery of protective anti-
bodies and immune cells contained in the colostrum
milk from the mother [56]. It has been shown at the
cellular level, that B- and T-cell development in pig-
lets starts four weeks after birth in the thymus and
yolk sac and comparable to humans the production
of immune cells shifts later in development to liver
and finally to bone marrow [57]. In minipigs, we de-
tect immune cell gene expression signatures between
Table 1 Preclinical minipig responses and clinical human responses of marketed drugs
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Response data were taken were taken from pre-clinical minipig drug safety toxicology studies or from public clinical trial databases. The interspecies target
similarity was calculated based on protein sequence alignment
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four and eight weeks after birth in spleen in bone
marrow (Fig. 4) resembling the expression mode in
humans.
Furthermore, the transcriptome analysis across safety-
relevant tissues presented here opens the possibility to
determine the time point during development at which
expression of a particular metabolic pathway or a CYP450
variant of interest is complete. We have shown based on
global transcript profiling that the developmental gene ex-
pression program is concluded about 4 weeks after birth
in virtually all organs. The only study addressing juvenile
toxicity in minipigs has investigated expression and activ-
ity of CYP3A4 during post-natal development [39]. Both
CYP3A4 protein and enzymatic activity are detectable 28
days after birth which is in agreement with the kinetics in
our dataset. Most target genes of marketed drugs
expressed in adult tissues (Additional file 10: Figure S5)
are detectable in equivalent juvenile tissue 4 weeks after
birth (data not shown). Based on the state of executed
transcriptional programs, four week old piglets should
give very similar pharmacological responses as adult mini-
pigs. Once confirmed by physiological data, this finding
would significantly reduce the quantity of compounds due
to the five-fold lower weight of piglets compared to adults.
In addition, the entire litter and cross-fostering could be
used for experiments assuring comparable genetic back-
ground thereby reducing outliers. This might be a consid-
erable advantage because we have shown above that the
number of genes with variable tissue expression is signifi-
cantly higher in minipig organs than in humans (Fig. 4).
The current transcriptional analysis further supports the
minipig as animal model in pre-clinical research and
pharmacology compliant with aims of the RETHINK pro-
ject [5] and the 3R-principles for animal welfare [45]. Cur-
rently, the use of non-human primates in biomedical
research is under heavy debate, and alternatives are con-
sidered especially in light of the recent advances in genet-
ics and molecular biology [58]. Stem-cell based human
models are gaining attention as in vitro models, and this
study, combined with the available databases released in
the public domain, will further promote the minipig as an
alternative model for non-human primates such as Cyno-
molgus macaque M. fascicularis. Finally, pigs offer the
unique opportunity of generation large animal models for
human disease using nuclear transfer from custom engi-
neered fibroblast cells. Current porcine models for human
disease include various cancers, cystic fibrosis, Duchenne
muscular dystrophy, autosomal polycystic kidney disease,
Huntington’s disease and spinal muscular atrophy [1].
Methods
Minipig tissue samples
Approval by an ethics committee was not required for this
study because all minipig tissue samples were obtained as
catalogue item from Ellegaard Göttingen Minipigs A/S,
Dalmose, Denmark (http://minipigs.dk/ordering/). All tis-
sues came from six naïve female and 6 male in accordance
with current animal welfare standards (http://minipigs.dk/
the-goettingen-minipig/animal-welfare/). Details (gender,
weight, age, family relationship) of all animals are on rec-
ord and are included in our microarray data submission
to GEOS.
Minipig genome sequencing
Genomic DNA was isolated using the QIAamp DNA
Mini Kit (Qiagen Inc., Valencia, CA, USA) from liver
tissue of a 1 year old female Göttingen minipig from
Ellegaard. For Roche-454-sequencing 1 μg of DNA was
mechanically sheared to an average length of 320 bases
and processed with the GS FLX Titanium Rapid Library
preparation kit. In addition, Roche-454 paired-end li-
braries with two end tags of ~140 base-pairs (bp), sepa-
rated by an eight kilobase (kb) insert, were generated
from 15 μg DNA with the GS FLX Titanium Paired End
Adaptor sets to improve unique read alignments and se-
quence gap-filling (Roche-454, Brandford, CT, USA). For
SOLiD-sequencing of 50 bp single-end reads, single frag-
ment libraries were generated from 5 μg sheared DNA
with the fragment library core kit. 5 μg of DNA were
used for the construction of a paired-end fragment li-
brary with 50 bp forward and 25 bp reverse reads and
1–3 kb insert size using the mate-paired library kit
(ABI/ LifeTechnologies, Carlsbad, CA, USA). All librar-
ies were amplified by emulsion PCR prior to sequencing.
Thirty-two Roche-454-FLX single-read and two paired-
end read runs were performed and complemented by
three SOLiD-3-plus single-end read runs and one
paired–end read sequencing run. Roche-454 long reads
and SOLiD short reads were mapped and assembled to
the Duroc reference genome (Sscrofa 10.2) by using a
template-based approach as described previously [41].
Only reads mapping uniquely to the template reference
genome were incorporated into the minipig genome as-
sembly. In addition, Roche-454 reads that could not have
been anchored to chromosomes of the minipig genome
were assembled de-novo with the Roche-454 Newbler
software (version 2.5.3).
Porcine specific transcripts
Normalized Roche-454 SAGE (serial analysis of gene ex-
pression) libraries of RNA reads were combined with
paired-end Illumina Genome Analyser RNA reads and
assembled in 3’686 contigs longer than 500 nucleotides
using Roche-454 Newbler (version 2.5.3) and Trinity
[59] software packages with default algorithm parame-
ters, respectively (Additional file 7: Figure S3). By apply-
ing BLAST [16], the resulting contig pool was mapped
on the predicted minipig mRNAs, RefSeq pig mRNAs
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and Swiss-Prot in order to remove protein-coding tran-
scripts. Next, we applied Genomic Mapping and Align-
ment Program (GMAP) [60] to deplete contigs matching
other vertebrate genomes: a total of 16 genomes (cow,
horse, dog, human, orang utan, chimpanzee, cynomolgus
monkey, rhesus monkey, marmoset, rabbit, guinea pig,
hamster, mouse, rat, opossum, chicken) was utilized.
This workflow generated a set of 133 pig-specific long-
non-coding RNAs, which exhibited significant expres-
sion above 10 RPKM (reads per kilobase of transcript
per million reads mapped) as determined by Illumina
paired-end sequencing and SOLiD Serial Analysis of
Gene Expression (SAGE).
African pig genome sequencing
Genomic DNA was isolated using the QIAamp DNA
Mini Kit (Qiagen Inc., Valencia, CA, USA) from blood
samples of an African Warthog (Phacochoerus africanus)
and two Bushpigs (Potamochoerus larvatus) obtained
from the International Livestock Research Institute,
Kenya (ILRI). 1 μg DNA was used as input for the Ion
Xpress Plus genomic DNA fragment library preparation
kit for whole-genome shotgun sequencing. After emul-
sion PCR, libraries with a median size of ~250 bp were
subjected to semiconductor sequencing using the Ion
Proton system (LifeTechnologies, Carlsbad, CA, USA).
Reads were mapped with GMAP (http://www.gmaptoo-
l.eu/en) to the minipig genome draft as described above.
RNA sequencing
Total RNA was extracted from minipig testis using the
RNeasy Mini kit combined with DNase treatment on a
solid support (Qiagen Inc., Valencia, CA, USA). For
unstranded RNA sequencing, 4 μg total RNA were ei-
ther treated with oligo(dT)25 Dynabeads to enrich poly-
A RNA or with the Ribo-Zero Magnetic Gold kit for
hybridization dependent depletion of ribosomal RNA
(Epicentre, Madison, WI, USA). Poly-A selected and
ribosomal depleted RNA was used for Illumina library
generation with the ScriptSeq v2 RNA-seq kit. 100 bp
paired-end sequencing was performed on an Illumina
Genome Analyzer IIX . For Roche-454 sequencing, poly-
A selected and ribosomal depleted RNA was used for
random primed cDNA (complementary DNA) library
generation with the Roche cDNA-synthesis system in
combination with the GS FLX Titanium Rapid Library
preparation kit. The SOLiD SAGE kit was used to gener-
ate a library of 27 bp tags per transcript with from poly-
A enriched and ribosomal depleted RNA (ABI/Life-
Technologies, Carlsbad, CA, USA). After emulsion PCR,
Roche-454 and SOLiD libraries were sequenced as
single-end read runs on a Roche-454 FLX or the SOLiD-
3-plus sequencing system. Roche-454 and SOLiD SAGE
reads were combined with paired-end Illumina reads to
assemble and quantify contigs with longer than 500 base
pairs using Roche-454 Newbler (version 2.5.3) or Trinity
assembler software with default algorithm parameters,
respectively [59].
Design of minipig specific microarrays
We have used our predicted minipig transcriptome com-
plemented by non-overlapping pig mRNA sequences
from the RefSeq database for custom microarray design
to monitor the expression of ~17,000 genes. For this
type of microarray, 60-mer oligonucleotide hybridization
probes were manufactured either with NimbleGen
photolithography or with Agilent inkjet printing technol-
ogy after closure of Nimblegen’s microarray business
segment. Using technical replicates and ERCC (external
RNA controls consortium) spike in controls, these mi-
croarrays exhibited a high reproducibility within repli-
cates (mean r2 = 0.994; n =12) and an average dynamic
range of 8 log2 units (n = 12). The lower limit of detec-
tion was determined with ERCCs at the signal level of
random probes, which serve as a metric of non-specific
annealing and background fluorescence. Furthermore we
used SOLiD and Roche-454 RNA-sequencing data from
four minipig tissues (liver, spleen, heart, kidney) to proof
that the in silico designed probes matched to experimen-
tally determined mRNA sequences. As it turned out, the
full-length sequence of ~80 % of all probes was present
in the transcript pool, ~10 % of the probes had imperfect
homology, and ~10 % of all probes had no match to the
RNA-sequencing data.
Microarray-based gene expression analysis
Minipig tissues were homogenized in tubes prefilled
with 1.4 mm ceramic beads and QiaGen’s lysis buffer
using a FastPrep-24 instrument (MP Biomedicals, Solon,
OH, USA). Total RNA from lysates was extracted using
the RNeasy Mini kit combined with DNase treatment on
a solid support (Qiagen Inc., Valencia, CA, USA). RNA
quality assessment and quantification was performed
using microfluidic chip analysis on an Agilent 2100 bioa-
nalyzer (Agilent Technologies Inc., Santa Clara, CA,
USA). For NimbleGen microarrays, 10 ng of total RNA
was used to prepare cDNA on a Biomek FXp work-
station (Beckman Coulter Inc., Brea, CA, USA) with
the NuGen Ovation Pico WTA System V2 (NuGEN
Technologies, Inc., SanCarlos, CA, USA), followed by
Cy3 labeling of cDNA with the Roche NimbleGen
One Color DNA Labeling Kit. NimbleGen 12x135K
gene expression microarrays (Design-ID 120229_Mini-
Pig_TH_expr_HX12) were hybridized with 4 μg of
Cy3-labeled cDNA (copyDNA) for 16 h at 42 °C. For
Agilent microarrays, 100 ng of total RNA was used to
prepare Cy3-labled cRNA (copyRNA) using the
Agilent Low Input Quick Amp Labeling kit (Agilent
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Technologies Inc., Santa Clara, CA, USA), followed
by QiaGen RNeasy column purification. 600 ng Cy3-
labelled cRNA was fragmented at 60 °C for 30 min
and hybridized to Agilent SurePrint G3 Custom GE
Arrays 8x60K (Design-ID 050244) for 17 h at 65 °C
in a rotating Agilent hybridization oven. After
hybridization, NimbleGen and Agilent microarrays
were washed and dried according to the manufac-
turer’s instruction. Microarray data was collected by
confocal scanning using the Roche NimbleGen MS200
Microarray Scanner at 2 μm pixel resolution (Roche
NimbleGen, Inc., Madison, WI, USA). Probe inten-
sities were subjected to Robust Multi-Array Analysis
(RMA) with background correction and quantile
normalization. Averaged gene-level signal intensities
were summarized into gene calls and log2 trans-
formed. Data analysis and visualization was performed
using Partek Genomics Suite version 6.6 (Partek, Inc.,
St. Louis, MI, USA), Spotfire version 6.5.2 (Tibco
Software Inc, Boston, MA, USA), and the R software
for statistical computing and graphics (R-Develop-
ment-Core-Team 2008. R: A language and environ-
ment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria). Enrichment
analysis of Gene Ontology (GO) annotations was per-
formed using the DAVID Bioinformatics Resource
(https://david.ncifcrf.gov/).
Definition of human tissue gene expression signatures
Tissue-specific gene signatures were identified from
three datasets: NB [30] and GNF [61], both based on
Affymetrix microarrays, and GTEx [62]. Gini index
[63] was used to identify tissue-specific genes. The
calculation of the Gini index was performed in “R”
using the “ineq” package. The Gini index ranges be-
tween zero (gene is ubiquitously and uniformly
present or abenst in all tissues) and one (gene is ex-
clusively expressed in one tissue). We define a gene
as a tissue signature gene if the Gini index equals 0.7
or greater.
Human reference microarray data analysis
For comparison of minipig with human mRNA expres-
sion values we used a public data set from NCBI Gene
Expression Omnibus (accession no. GSE3526). Human
tissues from 3 to 9 different adult Caucasian donors
were analyzed on Affymetrix HG-U133-PLUS_2 chips.
For inter-species comparisons expression data from
16,032 common genes and 13 common tissues was
normalized using the Global Rank-invariant Set
Normalization (GRSN) to reduce systematic distortions
in microarray data [31].
Metabolic activity measurements
Hepatocyte suspension cultures were prepared from
commercial cryopreserved hepatocytes from non-
transplantable liver tissues purchased from Promocell
(Vitaris AG, 6340 Baar, Switzerland). For minipig, com-
mercially available cryopreserved male Göttingen minipig
hepatocytes were purchased (BioreclamationIVT, USA,
Product Number M00615, lot Number XNG). Suspension
cultures were grown with gentle shaking in William’s
media supplemented with glutamine, antibiotics, insulin,
dexamethasone and 10 % fetal calf serum (FCS). The final
concentration of the reporter substrates midazolam,
dextromethorphan, diclofenac, tolbutamide, bupropion
and 7-hydroxycoumarin was 1 μmolar. O6-benzyl guan-
ine, tacrine, SN-38 and sulfamethazine were incubated
from 2.5, 10, 50 to 50 μmolar. Hepatocytes were grown in
96-well suspension cultures (1 million cells/ml) in plates
shaking (900 revolutions per minute) for 2 h in a 5 % CO2
atmosphere at 37 °C. At defined time points, 100 μl of the
cell suspension in each well was quenched with 200 μl
acetonitrile containing an internal standard. Samples were
then cooled and centrifuged followed by quanitification by
using liquid chromatography and mass spectrometry
(LC-MS/MS). The parameter settings for LC/MS analyte
detection in positive or negative ion MRM mode are sum-
marized in Additional file 11: Table S6. The Shimadzu
HPLC (high pressure liquid chromatography) system
consisted of 10ADvp pumps connected to a 5000 AB
Sciex mass spectrometer equipped with a TurboIon-
Spray source (IonSpray Voltage 4500V in negative
mode) and a HTS CTC PAL autosampler. For 1-OH
midazolam, benzydamine N-oxide, daunorubicinol, N-
acetyl-sulfamethazine, SN-38 glucuronide, 8-oxo-O6-
benzylguanine, hydroxybupropion, 4-hydroxydiclofenac,
dextrorphan and hydroxytacrine, a 50 × 2 mm analytical
column with 5 μm particle size Phenomenex Gemini C18
110A resin was used. 7-hydroxycoumarin glucuronide and
sulfate, were chromatographed using a 50 cm× 2 mm
column with Phenomenex, Synergi Hydro-RP 80 Å resin
with 4 μm particle size at 40 °C. Mobile phase A was 0.2
% formic acid in water, mobile phase B was 0.1 % formic
acid in water/methanol 95:5. 1 μl aliquots of the centri-
fuged sample solutions were injected and transferred onto
the analytical column at a flow rate of 0.50 mL/min using
95 % mobile phase A. To elute the compounds, a high
pressure, linear gradient from 5 to 95 % B in 98 s was
applied. A minimum of 6 calibration standards with a pre-
cision of 20 % and accuracy between 80 and 120 % were
used for calibration. Data analysis was performed using
weighted (1/x2) linear regression on analyte/internal
standard area ratios. For data analysis, Analyst 1.4.2 soft-
ware was used. To derive metabolic rates, the determined
concentrations of the metabolites were plotted against
time and a linear fit made to the data with emphasis upon
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the initial linear rate. The initial linear rate was then used
to derive at the metabolite formation rate (pmol/min/
million cells).
Availability of supporting data
The minipig whole genome shotgun project has been
deposited at DDBJ/EMBL/GenBank under the accession
LIDP00000000. The microarray data from this study
have been deposited at the NCBI Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/)
under accession numbers GSE71438 and GSE71441.
PDB code for crystal structures (http://www.rcsb.org/):
3G8I, 1FLT.
Additional files
Additional file 1: Table S1. Minipig genome assembly statistics.
Only reads mapping uniquely to the Duroc sus scrofa reference
genome were incorporated into the minipig genome assembly.
(DOCX 13 kb)
Additional file 2: Table S2. Contig assembly statistics. Roche-454 reads
that were not incorporated into the minipig genome were assembled
de-novo with Roche-Newbler software. (DOCX 13 kb)
Additional file 3: Table S3. Mapping rates of Duroc gene sequences to
available porcine genomes. (DOCX 13 kb)
Additional file 4: Figure S1. Sequence comparisons across different
pig species. 20’786 gene sequences from the Duroc pig genome Sus
Scrofa 10.2 as from ENSEMBL were mapped onto the genomes of Roche
minipig, the de novo assembled Göttingen minipig from Vamathevan et
al. and the Tibetan Pig v1.0 from Novogene using Blast. For each of the 3
pig genomes, the relative number of the orthologous gene sequences
was plotted against the sequence identities to the Duroc pig genes.
(JPEG 606 kb)
Additional file 5: Table S4. Disrupted minipig orthologs of human
protein coding genes. (DOCX 14 kb)
Additional file 6: Figure S2. Sequence analysis of the HEPN1
pseudogene. Alignment of the human HEPN1 mRNA sequence
(NM_001037558) with orthologs from the minipig, the Duroc Pig,
Phacochoerus africanus (Warthog) and Potamochoerus larvatus (Bushpig.
The A/G start-codon mutation is highlighted in green, insertions or
deletions are in yellow, stop-codons in red and conserved sequences
are colored in magenta. (PDF 115 kb)
Additional file 7: Figure S3. Schematic description of the in silico
workflow for selection of Sus scrofa specific lncRNAs. * 16 genomes: cow,
horse, dog, human, orang utan, chimpanzee, cynomolgus monkey, rhesus
monkey, marmoset, rabbit, guinea pig, hamster, mouse, rat, opossum,
chicken. See text for more detailed description. (JPEG 854 kb)
Additional file 8: Figure S4. Sequence alignment of 133 minipig
lncRNAs with genomic copies in the Roche minipig, the de novo
assembled minipig from Vamathevan et al., the Tibetan boar and the
Duroc pig. The color scale indicates the alignment coverage or presence
of the lncRNAs within the corresponding genomes. 100 % presence and
absence are denoted by black and yellow, respectively. The red box
zooms into regions with incomplete coverage. Parts of the mismatches
are likely due to misassembled loci (see text for details). (JPEG 1544 kb)
Additional file 9: Table S5. Mapping rates of Bushpig and Warthog
WGS reads to minipig lncRNA sequences. (DOCX 28 kb)
Additional file 10: Figure S5. mRNA expression levels of target genes
of marketed therapeutic antibodies in human and minipig tissues. Radar
chart (log scale) plotting shows expression levels of human drug targets
starting clockwise at the green arrow on top clockwise. Expression levels
of the following genes are displayed: ADRA1A, ADRA1B, ADRB1, ADRB2,
C5, CD33, CD3D, CTLA4, EGFR, ERBB2, FDPS, IL1B, IL2RA, IL6R, INSR, ITGA4,
ITGAL, MS4A1, MTOR, PPP3CA, PTGS1, PTGS2, RXRB, RXRG, TNF, TNFRSF8,
TNFSF13B, VEGFA. The blue line shows normalized human expression
levels (log2 levels), and the red line depicts equivalent minipig data in
each tissue. The dotted black circle marks the adapted detection limit of
the microarray platforms used. The circular grey background scale shows
the scale in two log2 intervals. (JPEG 3537 kb)
Additional file 11: Table S6. Parameter settings for LC/MS analyte
detection in positive or negative ion MRM mode. (DOCX 14 kb)
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